Abstract
The discovery that treatment of Kawasaki disease with intravenous immunoglobin (IVIG) could improve symptoms and lower the risk of developing coronary artery aneurysms was a major breakthrough. Now children with Kawasaki disease are routinely treated with IVIG and the outcome has greatly improved. A vexing problem is the patient with Kawasaki disease who is resistant to treatment with (IVIG). The mechanism underlying this non-response has not been clear. A Polymorphism in Plasma Platelet-activating Factor Acetylhydrolase is Involved in Resistance to Immunoglobulin Treatment in Kawasaki DiseaseThe Journal of PediatricsVol. 147Issue 1PreviewTo investigate whether reduced levels of plasma platelet-activating factor acetylhydrolase (PAF-AH) as a result of a genetic polymorphism are involved in the pathogenesis of Kawasaki disease (KD). Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
